36 results
ARS
2024 FY
ABSI
Absci Corp
23 Apr 24
Annual report to shareholders
4:10pm
.......................................................................................................................... 78 Item 4. Mine Safety Disclosures … better safety profiles in patients. Hence, building large training data sets for biologic drugs interactions offers the potential for AI models
8-K
EX-1.1
ABSI
Absci Corp
28 Feb 24
Absci Announces Proposed Public Offering of Common Stock
4:06pm
to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants … , distribution, storage, marketing, advertising, promotion, sale, export, import, use, handling, safety, efficacy, or manufacturing of pharmaceutical
424B5
ABSI
Absci Corp
28 Feb 24
Prospectus supplement for primary offering
8:34am
identity, safety, strength, quality, and purity. The FDA may convene an advisory committee, typically a panel that includes clinicians and other … experts, to provide clinical insight on applications which present difficult questions of safety or efficacy and to review, evaluate and recommend whether
8-K
ABSI
Absci Corp
27 Feb 24
Results of Operations and Financial Condition
4:45pm
and preserve the product’s identity, safety, strength, quality, and purity. The FDA may convene an advisory committee, typically a panel that includes … clinicians and other experts, to provide clinical insight on applications which present difficult questions of safety or efficacy and to review, evaluate
424B5
worxvk 47k
27 Feb 24
Prospectus supplement for primary offering
4:40pm
8-K
EX-1.1
ofbcw2f53m3 hrjq1
16 Jun 23
Entry into a Material Definitive Agreement
4:23pm
ARS
69b9mbl25tdmo
28 Apr 23
Annual report to shareholders
12:00am
8-K
EX-3.1
w8xy4
16 Dec 22
Amendments to Articles of Incorporation or Bylaws
4:07pm
DEF 14A
belbmc 0qypeiwu4
26 Apr 22
Definitive proxy
4:39pm
10-K
ry8dvv 52atb
22 Mar 22
Annual report
5:20pm
10-Q
weh9bd
7 Sep 21
Quarterly report
8:48am